A preclinical study using permanent middle cerebral artery occlusion in rats showed that chronic treatment with the Sigmar1 agonist cutamesine (SA4503) for a period of 28 days enhanced functional recovery after experimental stroke without affecting infarct size when treatment was initiated within 48 h (Ruscher et al., 2011). The gene discussed is SIGMAR1; the disease is stroke disorder.